Axel Merseburger, ASCO 2022: Highlights in prostate cancer clinical trials – Phase 3 SHR3680 trial, ENZAMET trial, MAGNITUDE trial, PROPEL trial, phase 2 lutetium 177 trial, VISION trial

ASCO 2022 showcased many important studies in prostate cancer. Prof. Axel Merseburger (Department of Urology, University of Lubeck, Germany), touchONCOLOGY’s Editor-in-Chief, joins us to share his highlights.

In this interview he discusses: the phase 3 trial of SHR3680 versus bicalutamide in combination with androgen deprivation therapy in patients with prostate cancer (0:40); the interim overall survival results in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (1:33); a study investigating ICE collaboration in clinical endpoints in rPFS and cPFS that appear to be valid surrogate endpoints for OS in prostate cancer (2:00); the first results of the phase 3 MAGNITUDE trial, and PROPEL trial (2:39), phase 2 lutetium 177 trial, and phase 3 VISION trial, targeted radioligand therapy with lutetium 177 vipivotide tetraxetan (3:20). Finally, he discusses a study around SUV mean that was shown to be strongly associated with overall survival in PSMA imaging in prostate cancer (4:41).

ASCO 2022 Abstracts discussed in this interview:

1. Abstract #5005: A phase 3 trial of SHR3680 versus bicalutamide in combination with androgen deprivation therapy (ADT) in patients with high-volume metastatic hormone-sensitive prostate cancer (mHSPC)
2. Abstract #LBA5004: Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC)
3. Abstract #5006: Assessing intermediate clinical endpoints (ICE) as potential surrogates for overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC)
4. Abstract #12: Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations

5. Abstract #5001: Lu-PSMA-617 in PSMA-positive metastatic castration-resistant prostate cancer: Prior and concomitant treatment subgroup analyses of the VISION trial

Disclosures: Axel Merseburger has nothing to disclose in relation to this video interview.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.

Filmed in coverage of the 2022 American Society of Clinical Oncology (ASCO) annual meeting.